Insulin Delivery Devices Market: Revolutionizing Diabetes Management

The global insulin delivery devices market is projected to reach USD 46.2 Billion by 2028 from an estimated USD 30.8 Billion in 2023, at a CAGR of 8.5% during the forecast period. The demand for better insulin delivery devices has become more important as diabetes prevalence has increased. Additionally, technological developments have made it possible for the market to receive solutions that are incredibly flexible. Other significant drivers of market growth include technological advancements in insulin delivery devices, government support and favourable reimbursement schemes for insulin delivery devices as well as growing prevalences of diabetic population. However, during the forecast period, growth in this market is anticipated to be restricted by aspects like high cost and lack of reimbursement in developing countries.

To know about the assumptions considered for the study download the pdf brochure

The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formerly Becton, Dickinson and Company Diabetes Care Business (US), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Sungshim Medical Co., Ltd. (South Korea), Vicentra B.V. (Netherland), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS) (US)

The company was formed through a spin-off the diabetes care business from Becton, Dickinson and Company (BD) in April 2022. The business offers a strong product portfolio of insulin syringes and pen needles and focuses on developing innovative products in the field of diabetes care through partnerships with leading companies in the healthcare sector. Company’s global manufacturing, distribution networks and commercial team help to produce and distribute products healthcare providers and end users in over 100 countries. It has its manufacturing sites located in US, China and Ireland. Embecta Corp. has partnered with leading companies in the healthcare sector in recent years to develop innovative products in the field of diabetes care. The company emphasizes on growing its presence across the world, which gives it access to more resources for production and better customer service. For instance, the company will partner with Tidepool to develop an automated insulin Delivery (AID) system for the people living with type 2 diabetes in May 2023.

Novo Nordisk A/S (Denmark)

The company operates in two business segment based on therapies namely Diabetes and Obesity care and Rare disease. The company’s Diabetes and Obesity segment has broad product portfolio, which includes different types of insulin, insulin pens and needles, obesity delivery system, GLP-1 analog, glucagon and oral diabetic drugs. The business is present throughout the world, including North America, Europe, Latin America, Africa, the Middle East, and Asia Pacific. NovoPen4, FlexPen, NovoPen 6, NovoFine Plus, FlexTouch, NovoPen Echo Plus are all part of Novo Nordisks product portfolio for insulin delivery devices. The company emphasizes on product launching, innovative products and establishing partnerships and alliances with other market participants in order to maintain its leading position in the market.

Medtronic PLC (Ireland)

In 2022, Medtronic held the third-position in the market for insulin delivery devices. The company is a leading providers of medical devise, medical technology services, and solutions. The company operates in four segments that develop, manufacture, distribute and sell device based medical therapies and services: the cardiovascular portfolio, the medical surgical portfolio, the neuroscience portfolio, and the diabetes operating unit. The diabetes operating unit develops, manufactures, and markets products and services for type 1 diabetes and type 2 diabetes. The geographic reach of Medtronic is in North America, Europe, Asia Pacific, and Latin America. To keep up its market dominance, the company mainly focuses on product launches and alliances and collaborations. Minimized 670G, Minimed 630G are egs of the insulin pumps which has gained huge popularity in recent years.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092

Insulin Delivery Devices Market Dynamics:

Drivers:

Growing prevalence of diabetic population
Restraints:

High cost and lack of reimbursement in developing countries
Opportunities:

Increasing healthcare expenditure on diabetes care
Challenges:

Needlestick injuries and misuse of injection pens
Insulin Delivery Devices Market Advantages:

Enhanced Convenience: Insulin delivery devices provide a convenient and user-friendly way for patients to administer insulin. Whether it's insulin pens, pumps, or patches, these devices simplify the process of insulin delivery, reducing the reliance on traditional syringes and vials.
Improved Glycemic Control: The advanced features of insulin delivery devices, such as smart pumps with continuous glucose monitoring (CGM) integration, allow for more precise and personalized insulin dosing. This results in better glycemic control, reducing the risk of hyperglycemia and hypoglycemia episodes, and ultimately lowering the risk of diabetes-related complications.
Increased Treatment Compliance: Insulin delivery devices offer greater ease of use and convenience, leading to improved treatment compliance among patients. The reduction in the number of injections or the need for frequent adjustments in insulin dosing can positively impact patient adherence to their prescribed treatment plan.
Precision and Accuracy: Insulin delivery devices are designed to deliver insulin with greater precision and accuracy, ensuring consistent dosing. This reduces the potential for dosing errors and ensures patients receive the correct amount of insulin they need.
Flexibility in Lifestyle: Insulin pumps and patch-based systems offer more flexibility for patients in managing their diabetes. With programmable basal rates and bolus doses, patients can adjust their insulin delivery to match their lifestyle, exercise, and dietary habits.
Reduced Pain and Discomfort: Insulin delivery devices often use finer needles or even needleless systems, which can lead to reduced pain and discomfort during insulin administration compared to traditional syringes.
Continuous Glucose Monitoring (CGM) Integration: Many modern insulin pumps come with CGM integration, allowing real-time monitoring of glucose levels. This feature helps patients proactively adjust insulin dosing and provides insights into glucose trends, enabling more proactive diabetes management.
Potential for Closed-Loop Systems: The insulin delivery device market is rapidly progressing toward closed-loop or artificial pancreas systems, where insulin delivery is fully automated based on continuous glucose monitoring data. This technology has the potential to revolutionize diabetes management by minimizing the need for constant manual intervention.
Improved Data Tracking and Analysis: Insulin delivery devices often come with software or mobile apps that enable patients to track and analyze their blood glucose levels, insulin dosing, and other relevant data. This facilitates better self-management and empowers patients to make informed decisions about their diabetes care.
Advancements in Telemedicine: The integration of insulin delivery devices with telemedicine platforms allows healthcare providers to remotely monitor patients' glucose levels, adjust insulin therapy, and provide timely feedback, fostering a more personalized and accessible approach to diabetes management.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=107632092